Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis

ATTR-specific treatment and AVR both result in significant survival benefit in dual pathology AS and ATTR-CA. Results should be interpreted in the context of the non-randomized study setting and differences in patient characteristics.

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2025-06-02
DOI
https://doi.org/10.1093/eurheartj/ehaf362
Citations
15
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
12.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis

James Moon, Julia Mascherbauer, Simone Longhi, Philipp Emanuel Bartko et al.
15 citations
European Heart Journal
Amyloidosis: Diagnosis, Treatment, Outcomes
12.09
article

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis

James Moon, Julia Mascherbauer, Simone Longhi, Philipp Emanuel Bartko, Hannah Rosenblum, Teresa Maria Capovilla, Teresa Capovilla, Robin Ristl, Carolina Donà, Kseniya Halavina, Jan M. Griffin, Thomas A. Treibel, Christian Nitsche, Ashraf Hamdan, João L. Cavalcante, Μαρία Παπαθανασίου, Hannah R Rosenblum, Sigita Glaveckaitė, Andreas Kammerlander, Laurenz Hauptmann, Marianna Fontana, Andrea Lalario, Steven A. Muller, Stephan Dobner, Franz Duca, Marco Merlo, Stefan Stortecky, Andreas Schuster, Paul Scully, Michael Poledniczek, Matthias Koschutnik, Aldostefano Porcari, Kush Patel, Elena Biagini, Christina Kronberger, Marish I.F.J. Oerlemans, Andrew Kelion, Francisco Gama, Maximilian Autherith, Lara Schlender, Ali Yılmaz, Torben Lange, Christian Hengstenberg, Nuriye Akyol, Matthew Maurer
article en
15 citations

Abstract

ATTR-specific treatment and AVR both result in significant survival benefit in dual pathology AS and ATTR-CA. Results should be interpreted in the context of the non-randomized study setting and differences in patient characteristics.

European Heart JournalVol. 46(44)
Goethe University Frankfurt (DE), University of Bern (CH), St Bartholomew's Hospital (GB), NewYork–Presbyterian Hospital (US), University of Trieste (IT), Medical University of South Carolina (US), Tel Aviv University (IL), Vilnius University (LT), Columbia University Irving Medical Center (US), Rabin Medical Center (IL), New York Hospital Queens (US), University Hospital of Bern (CH), The Royal Free Hospital (GB), John Radcliffe Hospital (GB), University Medical Center Utrecht (NL), University Hospital Münster (DE), Amyloidosis Foundation (US), Universitätsmedizin Göttingen (DE), Azienda USL di Bologna (IT), Hospital de Santa Cruz (PT), University Hospital Frankfurt (DE), Minneapolis Heart Institute Foundation (US), ERN GUARD-Heart (NL), Karl Landsteiner University of Health Sciences (AT), West German Heart and Vascular Center Essen (DE), Azienda Sanitaria Universitaria Integrata di Trieste (IT), University College London (GB), University of Göttingen (DE), Medical University of Vienna (AT)
Pfizer
Good health and well-being
Openalex Percentile: Top 1%
Amyloidosis: Diagnosis, Treatment, Outcomes
12.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.